Burlington, Ontario

THE JENEX CORPORATION (“Jenex” or the “Corporation”) (TSX Venture Exchange – JEN), Michael Jenkins, President and CEO of Jenex is pleased to announce the following:

A.) The Jenex Corporation will offer up to 1,800,000 units at Fourteen Cents ($0.14) per Unit, in a brokered private placement. The private placement will have gross proceeds of $252,000 upon the maximum placement of all units. “Units” under the Private Placement consist of one (1) Common Share and a fraction of a Common Share Purchase Warrant (equal to about 0.14 of a Warrant), such that the Purchaser will receive one (1) whole warrant for every One Dollar ($1.00) invested.  Each whole Warrant will be non-transferable and will entitle the holder to purchase one Common Share at a price of Twenty-Five Cents ($0.25), if exercised on or before twenty four (24) months after the Closing Date.  

B.) The Jenex Corporation has arranged a $500,000 brokered financing consisting of Series B Convertible Debentures of five hundred thousand (500,000) units.  “Units” in the Series B Convertible Debenture consist of One Dollar ($1.00) principal amount of the Convertible Debenture and three and one/half (3.5) Common Share Purchase Warrants. The Series B Convertible Debenture shall accrue interest at a rate of Twelve Percent(12%) per annum and have a term of 24 months.  The conversion price of this Debenture and the accrued but unpaid interest thereon, is convertible into shares at fifteen Cents ($0.15) per share. Each whole Common Share Purchase Warrant will be non-transferable and will entitle the holder to purchase one Common Share at a price of Twenty-Five Cents ($0.25), if exercised on or before  twenty four (24) months after the Closing Date. The Convertible Debentures are callable by the Corporation at its` discretion in full or in part.

C.)  The Jenex Corporation has arranged a $275,000 brokered financing, consisting of  Series C Convertible Debentures of two hundred and seventy-five thousand (275,000) units.  “Units” in the Series C Convertible Debenture consist of One Dollar ($1.00) principal amount of the Convertible Debentures and one (1) Common Share Purchase Warrant. The Series C Convertible Debenture shall accrue interest at a rate of Twelve Percent (12%) per annum and have a term of 24 months.  The conversion price of this Debenture and the accrued but unpaid interest thereon, is convertible into shares at fifteen Cents ($0.15) per share. Each whole Common Share Purchase  Warrant will be non-transferable and will entitle the holder to purchase one Common Share at a price of Twenty-Five Cents ($0.25), if exercised on or before twenty four (24) months after the Closing Date. The Convertible Debentures are callable by the Corporation at its` discretion in full or in part. 

The loan and warrant transaction announced in a press release dated April 29,2005 is being amended as follows: 1) The bonus warrants of one million two hundred and fifty thousand (1,250,000) Warrants exercisable at $0.14 per common share, has been rescinded. 2)  The issuance of 300,000 common shares at a deemed price of $0.105 as bonus shares to an arm’s length party as consideration for facilitating the loan has been rescinded. 

Closing is expected to be or about January 9, 2006. The net proceeds of the placements will be used for the company’s Canadian launch of their intercept^CS™ product for the prevention of cold sores and general working purposes. The securities issued pursuant to the private placements will be subject to applicable hold periods. The proposed transactions are subject to TSX Venture Exchange approval.

About The Jenex Corporation

Headquartered in Burlington, Ontario, the Corporation owns a patented Thermal Therapy Technology. Patents in the United States, Canada, Australia, and Europe protect the Technology.  The first device developed from this technology is the Therapik^® product, for insect stings and bites. Therapik^® has been approved as a Class II medical device in Canada and the United States.  Licensing partners are being pursued for world markets. The second device, intercept^CS is the first product proven and approved to prevent cold sores. Jenex has been approved to market intercept^CS in Canada with its approved claim, "For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks". The Corporation is preparing for the launch of intercept^CS in the Canadian market in first quarter 2006.

Enquiries:

Michael A. Jenkins, President

The Jenex Corporation

940 Sheldon Court, Suite 207

Burlington, Ontario

L7L 5K6

Telephone:  (905) 632-3830

Facsimile:    (905) 632-3774

Email:          jenex@jenexcorp.com